Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27899324 | 0.80 | KDM4E (0.61) | KDM4EMPOTRPV4L3MBTL1GLA | |
| SCHEMBL4502928 | 0.77 | LMNA (0.54) | KDM4EMPOTRPV4L3MBTL1GLA | |
| SCHEMBL1302732 | 0.72 | TRPV4 (0.49) | KDM4EMPOIDO1TDO2IDO2 | |
| SCHEMBL3700456 | 0.72 | ATM (0.57) | MPOTRPV4CASRHRH3 | |
| SCHEMBL30795730 | 0.70 | RAB9A (0.39) | MPOCYP3A4KMT2ACASR | |
| SCHEMBL15840322 | 0.69 | L3MBTL1 (0.49) | MPOIDO1TDO2IDO2TRPV4 | |
| SCHEMBL15538380 | 0.68 | KDM4E (0.61) | KDM4EMPOIDO1TDO2IDO2 | |
| SCHEMBL13363284 | 0.67 | PARP14 (0.43) | KDM4E | |
| SCHEMBL3708958 | 0.65 | TDO2 (0.44) | KDM4EMPOIDO1TDO2IDO2 | |
| SCHEMBL1161773 | 0.65 | HDAC6 (0.42) | KDM4ETRPV4CYP3A4L3MBTL1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269783-A1 | NOVEL 2,3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269783-A1 | NOVEL 2,3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNN3, KCNJ2, KCNN2 | KDM4E 1937/4885MPO 2206/4885IDO1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.